You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 10, 2025

CLINICAL TRIALS PROFILE FOR CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Cardene In 0.83% Sodium Chloride In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00325793 ↗ IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status PDL BioPharma, Inc. Phase 4 2004-01-01 Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00325793 ↗ IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status OSF Healthcare System Phase 4 2004-01-01 Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00528827 ↗ A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of CardeneĀ® I.V. in Pediatric Subjects With Hypertension Withdrawn Facet Biotech Phase 2 2007-09-01 To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.
NCT00765648 ↗ Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department Completed EKR Therapeutics, Inc Phase 4 2008-10-01 The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting.
NCT00765648 ↗ Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department Completed The Cleveland Clinic Phase 4 2008-10-01 The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cardene In 0.83% Sodium Chloride In Plastic Container

Condition Name

Condition Name for Cardene In 0.83% Sodium Chloride In Plastic Container
Intervention Trials
Hypertension 3
Cerebral Vasospasm 2
Hypertensive Urgency 1
Hypotensive Anesthesia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cardene In 0.83% Sodium Chloride In Plastic Container
Intervention Trials
Hypertension 3
Cerebral Hemorrhage 2
Vasospasm, Intracranial 2
Hypotension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cardene In 0.83% Sodium Chloride In Plastic Container

Trials by Country

Trials by Country for Cardene In 0.83% Sodium Chloride In Plastic Container
Location Trials
United States 18
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cardene In 0.83% Sodium Chloride In Plastic Container
Location Trials
Massachusetts 2
Texas 2
Ohio 2
Florida 2
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cardene In 0.83% Sodium Chloride In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Cardene In 0.83% Sodium Chloride In Plastic Container
Clinical Trial Phase Trials
Phase 4 6
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cardene In 0.83% Sodium Chloride In Plastic Container
Clinical Trial Phase Trials
Withdrawn 3
Recruiting 2
Terminated 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cardene In 0.83% Sodium Chloride In Plastic Container

Sponsor Name

Sponsor Name for Cardene In 0.83% Sodium Chloride In Plastic Container
Sponsor Trials
Vanderbilt University Medical Center 2
Yale University 1
Geisinger Clinic 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cardene In 0.83% Sodium Chloride In Plastic Container
Sponsor Trials
Other 22
Industry 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials and Market Analysis for Cardene in 0.83% Sodium Chloride

Introduction

Cardene, also known as nicardipine hydrochloride, is a calcium channel blocker used primarily for the treatment of hypertension and angina. Here, we will delve into the clinical trials, pharmacokinetics, and market analysis related to Cardene, particularly when administered in 0.83% sodium chloride in a plastic container.

Clinical Trials Overview

Pharmacokinetics and Efficacy

Clinical trials for Cardene have demonstrated its efficacy in managing hypertension and stable angina. The pharmacokinetics of Cardene are nonlinear due to saturable hepatic first-pass metabolism. This means that increasing doses result in a disproportionate increase in plasma levels. For example, increasing the dose from 20 mg to 30 mg every 8 hours more than doubled the peak plasma concentration (Cmax), and increasing the dose from 20 mg to 40 mg every 8 hours increased Cmax more than threefold[1].

Antianginal Efficacy

In patients with chronic stable angina, Cardene has been shown to increase exercise tolerance, reduce nitroglycerin consumption, and decrease the frequency of anginal attacks. Four placebo-controlled studies involving 258 patients demonstrated significant improvements in exercise tolerance, total exercise duration, and time to 1 mm ST segment depression[1].

Antihypertensive Efficacy

Cardene has also been effective in reducing blood pressure in patients with mild to moderate hypertension. Three placebo-controlled studies involving 517 patients showed dose-related decreases in both systolic and diastolic blood pressure at peak and trough levels, although the antihypertensive effect diminishes significantly by the end of the dosing interval[1].

Safety and Adverse Effects

Clinical Trial Findings

While peak responses were not associated with adverse effects during clinical trials, physicians should be aware of potential adverse effects. Hemodynamic studies showed significant increases in ejection fraction and cardiac output with minimal changes in left ventricular end-diastolic pressure (LVEDP). However, there were increases in heart rate, particularly at higher doses, with mean heart rate increases of 5 to 10 beats per minute compared to placebo[1].

Adverse Events in Recent Studies

A phase 2b randomized clinical trial investigating localized nicardipine release implants did not show an elevated risk profile for treatment-emergent or serious adverse events in the implant group compared to the control group. The study reported 180 treatment-emergent adverse events, with 96 in the control group and 84 in the implant group, and 16 serious adverse events, with 10 in the control group and 6 in the implant group[4].

Market Analysis

Current Formulation

The supplemental new drug application approved in 2008 introduced a new container closure system for Cardene I.V. in 0.83% sodium chloride, along with an increased concentration of nicardipine hydrochloride to 0.2 mg/mL. This formulation enhances the stability and convenience of the drug product[3].

Market Impact

The approval of the new formulation has likely improved the market position of Cardene by offering a more stable and convenient option for healthcare providers. However, the market for calcium channel blockers is competitive, with various other drugs available for hypertension and angina management.

Projections and Future Outlook

Regulatory Compliance

Given the recent approvals and updates to the formulation, Cardene is well-positioned to meet current regulatory standards. Continued compliance with FDA guidelines will be crucial for maintaining market presence.

Clinical Relevance

The sustained efficacy of Cardene over long-term dosing, as demonstrated in clinical trials, suggests a strong clinical relevance. This could lead to increased prescription rates and patient adherence, contributing to market growth.

Competitive Landscape

While Cardene has a established presence, the market for cardiovascular drugs is dynamic. New drugs and formulations may enter the market, potentially impacting Cardene's market share. However, its proven efficacy and safety profile will remain key factors in its market positioning.

Key Takeaways

  • Efficacy: Cardene has demonstrated significant efficacy in managing hypertension and stable angina through clinical trials.
  • Pharmacokinetics: The drug exhibits nonlinear pharmacokinetics, leading to disproportionate increases in plasma levels with dose increments.
  • Safety: While generally safe, Cardene can cause increases in heart rate and other adverse effects, particularly at higher doses.
  • Market: The new formulation in 0.83% sodium chloride enhances stability and convenience, but the market remains competitive.
  • Future Outlook: Continued regulatory compliance and clinical relevance are crucial for maintaining market presence.

FAQs

What is the primary use of Cardene?

Cardene (nicardipine hydrochloride) is primarily used for the treatment of hypertension and chronic stable angina.

How does the pharmacokinetics of Cardene affect its dosing?

The pharmacokinetics of Cardene are nonlinear due to saturable hepatic first-pass metabolism, resulting in disproportionate increases in plasma levels with dose increments.

What are the common adverse effects of Cardene?

Common adverse effects include increases in heart rate, particularly at higher doses, and other hemodynamic changes such as increases in ejection fraction and cardiac output.

Has the new formulation of Cardene in 0.83% sodium chloride been approved?

Yes, the new formulation was approved in 2008, introducing a new container closure system and an increased concentration of nicardipine hydrochloride to 0.2 mg/mL[3].

How does Cardene compare to other calcium channel blockers in the market?

Cardene has a proven efficacy and safety profile, but the market for calcium channel blockers is competitive, with various other drugs available for hypertension and angina management.

Sources

  1. CARDENE - accessdata.fda.gov
  2. Cardano (ADA) Price Prediction 2024 2025 2026 - 2030 - Changelly
  3. 019734Orig1s014 - accessdata.fda.gov
  4. Localized Nicardipine Release Implants for Prevention of ... - jamanetwork.com
  5. Cardano Price Prediction 2025: ADA All-Time High Could Be in Sight - ccn.com

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.